IDEXX Laboratories: Q1 Earnings Insights

 

Shares of IDEXX Laboratories IDXX were unchanged after the company reported Q1 results.

Quarterly Results

Earnings per share rose 82.17% year over year to $2.35, which beat the estimate of $1.71.

Revenue of $777,707,000 up by 24.17% year over year, which beat the estimate of $737,380,000.

Outlook

The upcoming fiscal year's EPS expected to be between $7.88 and $8.18.

The upcoming fiscal year's revenue expected to be between $3,105,000,000 and $3,160,000,000.

How To Listen To The Conference Call

Date: May 04, 2021

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/if4enin4

Recent Stock Performance

Company's 52-week high was at $573.99

Company's 52-week low was at $266.00

Price action over last quarter: Up 13.29%

Company Description

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!